SCHEMBL2212767

SCHEMBL2212767

O=c1[nH]c2cccc(F)c2cc1C1CCNCC1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.52
DDO Q99489 1/20 0.52
HTR6 P50406 2/20 0.43
HTR1A P08908 8/20 0.43
SLC6A2 P23975 8/20 0.43
SLC6A4 P31645 8/20 0.43
SLC6A3 Q01959 6/20 0.43
HTR2C P28335 4/20 0.42
ADRB2 P07550 1/20 0.42
HTR2A P28223 1/20 0.40
KCNH2 Q12809 1/20 0.40
TNKS O95271 2/20 0.39
TNKS2 Q9H2K2 2/20 0.39
APP P05067 1/20 0.38
KDM4E B2RXH2 1/20 0.38
PLAT P00750 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2211350 0.99 DAO (0.51) DAODDOHTR6HTR1ASLC6A2
SCHEMBL14394063 0.83 DAO (0.49) DAODDOHTR1ATNKSTNKS2
SCHEMBL3543444 0.78 DAO (0.52) DAODDOHTR6HTR1ASLC6A2
Hydrochloric Acid SCHEMBL2212880 0.77 DAO (0.51) DAODDOHTR6HTR1ASLC6A2
SCHEMBL105569 0.77 MAOB (0.48) DAODDOHTR2CADRB2
Hydrochloric Acid SCHEMBL31318331 0.75 HTR2C (0.48) DAODDOHTR2CADRB2
Hydrochloric Acid SCHEMBL2209444 0.75 HTR2C (0.48) DAODDOHTR2CADRB2
SCHEMBL13792217 0.75 SLC6A2 (0.40) HTR1ASLC6A2SLC6A4SLC6A3TNKS
Hydrochloric Acid SCHEMBL2210454 0.74 TNKS (0.39) SLC6A2SLC6A4SLC6A3HTR2CKCNH2
SCHEMBL6647233 0.73 HTR1A (0.43) HTR1ASLC6A2SLC6A4SLC6A3HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013213-B1 CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2011-07-27 EP disclosed
US-7544680-B2 Constrained compounds as CGRP-receptor antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-09 US disclosed
US-7470679-B2 Constrained compounds as CGRP-receptor antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2008-12-30 US disclosed
US-20080287422-A1 Constrained Compounds as CGRP-Receptor Antagonists BRISTOL-MYERS SQUIBB COMPANY 2008-11-20 US disclosed
US-7384930-B2 Constrained compounds as CGRP-receptor antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2008-06-10 US disclosed
US-7384931-B2 Constrained compounds as CGRP-receptor antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2008-06-10 US disclosed
WO-2007130860-A2 CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-15 WO disclosed
WO-2007130927-A2 CONDENSED TRICYCLIC COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-15 WO disclosed
US-20070259850-A1 CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259850-A1 CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS CALCR, BDKRB2, CALCRL DAO 4388/4885DDO 4227/4885HTR6 256/4885
US-20080287422-A1 Constrained Compounds as CGRP-Receptor Antagonists CALCR, BDKRB2, CALCRL DAO 4388/4885DDO 4227/4885HTR6 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.